Berberine ameliorates coronary artery endothelial cell injury in Kawasaki disease through complement and coagulation cascades.
10.7499/j.issn.1008-8830.2406075
- Author:
Jin-Wen LIAO
1
;
Xin GUO
1
;
Bo LIANG
;
Xu-Xia LI
;
Ming-Guo XU
Author Information
1. Department of Pediatrics, Third People's Hospital of Longgang District of Shenzhen, Shenzhen, Guangdong 518020, China.
- Publication Type:Journal Article
- Keywords:
Berberine;
Complement and coagulation cascade;
Coronary artery lesion;
Human coronary artery endothelial cell;
Kawasaki disease
- MeSH:
Mucocutaneous Lymph Node Syndrome/blood*;
Humans;
Endothelial Cells/pathology*;
Complement System Proteins/physiology*;
Coronary Vessels/drug effects*;
Male;
Blood Coagulation/drug effects*;
Berberine/therapeutic use*;
Female;
Child, Preschool;
Infant
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(1):101-108
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To explore the role of berberine (BBR) in ameliorating coronary endothelial cell injury in Kawasaki disease (KD) by regulating the complement and coagulation cascade.
METHODS:Human coronary artery endothelial cells (HCAEC) were divided into a healthy control group, a KD group, and a BBR treatment group (n=3 for each group). The healthy control group and KD group were supplemented with 15% serum from healthy children and KD patients, respectively, while the BBR treatment group received 15% serum from KD patients followed by the addition of 20 mmol/L BBR. Differential protein expression was analyzed and identified using isobaric tags for relative and absolute quantitation technology and liquid chromatography-tandem mass spectrometry, followed by GO functional enrichment analysis and KEGG signaling pathway enrichment analysis of the differential proteins. Western blot was used to detect differential protein expression.
RESULTS:A total of 518 differential proteins were identified between the KD group and the healthy control group (300 upregulated proteins and 218 downregulated proteins). A total of 422 differential proteins were identified between the BBR treatment group and the KD group (221 upregulated proteins and 201 downregulated proteins). Bioinformatics analysis showed that compared to the healthy control group, the differential proteins in the KD group were enriched in the complement and coagulation cascade and ribosome biogenesis in eukaryotes. Compared to the KD group, the differential proteins in the BBR treatment group were also enriched in the complement and coagulation cascade and ribosome biogenesis in eukaryotes. Western blot results indicated that compared to the healthy control group, the expression of complement C1q subcomponent subunit C (C1QC), kininogen-1 (KNG1), complement C1s subcomponent (C1S), and C4b-binding protein alpha chain (C4BPA) was increased in the KD group (P<0.05). Compared to the KD group, the expression of KNG1, C1S, C1QC, and C4BPA was decreased in the BBR treatment group (P<0.05).
CONCLUSIONS:The complement and coagulation cascade may be involved in the regulation of BBR treatment for coronary injury in KD, and C1QC, KNG1, C1S, and C4BPA may serve as biomarkers for this treatment.
